ClinicalTrials.gg
RecruitingNCT06855069Updated Dec 17, 2025

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Phase 3 interventional study of HS-20089 and Paclitaxel in Ovarian Cancer, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 392 studies in Ovarian Neoplasms with a site in China — 198 open to participants now, 231 under way, 35 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
28th of 319
468 · median 83
Started
2025
with 53 others
Phase 3
52 of 392
19 open now
Primary completion
2027-03
later than 117 of 230 live
Registered
309th of 392
by date

Among the 392 studies in Ovarian Neoplasms with a site in China, this one is the 28th largest by planned enrollment of the 319 interventional ones that give a count, is one of 54 that started in 2025, is one of 52 in phase 3, reaches primary completion later than 117 of the 230 other live ones, and was the 309th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

198 of the 392 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

193 more — sign in →

All 198 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Platinum-resistant recurrent epithelial ovarian cancer
  • HS-20089
  • randomized
  • phase III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation and written .
  2. 18 years and older, female.
  3. diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
  4. Patients must have platinum-resistant disease
  5. Be able to provide fresh or archived tumor tissue.
  6. At least one according to v1.1.
  7. (ECOG) score: 0-1.
  8. With a > 12 weeks.
  9. Adequate bone marrow reserve and organ function.
  10. is required during the trial.

Exclusion criteria

Exclusion Criteria:

  1. Prior treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.
  2. Previous or co-existing .
  3. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring clinical intervention.
  4. Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment.
  5. Unresolved ≥grade 2 toxicities from previous anticancer therapy.
  6. History of severe reactions to either the drug substances or inactive ingredients of HS-20089.
  7. Any serious or uncontrolled medical disorder in the opinion of the investigator that may increase the risk associated with the study participation or study drug administration.
  8. Other inappropriate situation considered by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
468 participants (estimated)

Study arms

  • Experimental
    Treatment group 1: HS-20089

    Drug: HS-20089

  • Active comparator
    Treatment group 2: Investigator's choice of chemotherapy

    Drug: Paclitaxel · Drug: Doxorubicin · Drug: Topotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) assessed by Blinded Independ Review Committee (BIRC) as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Screening up to study completion, an average of 1 year

  2. Objective Response Rate (ORR), assessed by site investigator as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

  3. Duration of Response (DoR), assessed by site investigator as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

  4. Disease Control Rate (DCR), assessed by site investigator as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

  5. Objective Response Rate (ORR), assessed by BIRC as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

  6. Duration of Response (DoR), assessed by BIRC as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

  7. Disease Control Rate (DCR), assessed by BIRC as per RECIST 1.1

    Time frame: Screening up to study completion, an average of 1 year

  8. Adverse Events

    Time frame: Screening up to study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 23 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Mar 7, 2027
CompletionEst.
Mar 7, 2029
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06855069
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Mar 13, 2025
Primary completion
Mar 7, 2027 (estimated)
Completion
Mar 7, 2029 (estimated)
Last update
Dec 17, 2025

Study contacts

Lingying Wu, MD
Contact
wulingying@csco.org.cn
(+86)13910865483
Lingying Wu, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mocertatug rezetecan

Start the discussion